

AD _____

Award Number: DAMD17-02-1-0605

TITLE: In Vivo p53 Signaling in Breast Epithelial Cells After Oncogenic Stimulus

PRINCIPAL INVESTIGATOR: Jamie M. Hearn
Dr. Jennifer Pietenpol

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center
Atlanta, GA 31192-0303

REPORT DATE: September 2005

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 01-09-2005	2. REPORT TYPE Annual Summary	3. DATES COVERED (From - To) 1 Sep 2002 – 31 Aug 2005	
4. TITLE AND SUBTITLE In Vivo p53 Signaling in Breast Epithelial Cells After Oncogenic Stimulus		5a. CONTRACT NUMBER	
		5b. GRANT NUMBER DAMD17-02-1-0605	
		5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jamie M. Hearnes Dr. Jennifer Pietenpol		5d. PROJECT NUMBER	
		5e. TASK NUMBER	
E-mail:		5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Vanderbilt University Medical Center Atlanta, GA 31192-0303		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)	
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			
13. SUPPLEMENTARY NOTES			
14. ABSTRACT One of the most frequent alterations in breast cancer is deregulation of the p53 tumor suppression signaling pathways. The tumor suppressor p53 is a sequence-specific transcription factor that is activated in response to various cellular stresses. It has been predicted that there are over 1500 consensus p53 binding sites present in the human genome. However, only a subset of p53 binding sites and correlated target genes have been identified to date, and characterization of p53 signaling pathways in their entirety is not yet complete. The goal of this study is to further define and characterize such pathways through the identification of novel genes that are directly regulated by p53. Using chromatin immunoprecipitation followed by a yeast selection system we have isolated over 100 genomic DNA fragments that contain novel p53 binding sites . The new DNA fragments obtained have been mapped to various regions of the human genome, and four novel p53 target genes have been identified and validated. This research will lead to a more complete understanding of p53-regulated signaling pathways in mammary epithelial cells.			
15. SUBJECT TERMS tumor suppressor p53, chromatin immunoprecipitation, p53 binding sites, p53 target genes			
16. SECURITY CLASSIFICATION OF:		17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 18
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	19a. NAME OF RESPONSIBLE PERSON USAMRMC
			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4-6
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6-7
Appendix.....	7-18

INTRODUCTION

As stated in my original grant proposal, the overall goal of my project was to explore the pivotal role that the transcription factor p53 plays in suppressing neoplastic transformation of the normal mammary epithelium. Specifically, I proposed to study p53 signaling pathways in primary mammary epithelial cells in response to oncogenic stress as compared to genotoxic stress. As outlined below and in the previous annual summaries the working hypothesis has been changed from looking at both oncogenic stress and genotoxic stress, to only genotoxic stress. The current hypothesis is **p53 protein levels in the cell and the heterogeneity of the p53 consensus DNA binding site contained within downstream target genes dictate p53 target gene selectivity in mammary epithelial cells after genotoxic stress.**

BODY

Task 1. To determine the kinetics of p53 binding to select target genes, quantify p53 protein levels, and assess the phosphorylation and acetylation status of p53 *in vivo* in human mammary epithelial cells after oncogenic stimulation.

- a. Obtain normal human mammary epithelial cells and mammary epithelial cell lines to be used in the following experiments and verify p53 status (Months 1-3) (Figure 1).

COMPLETED

- A purification process for primary human mammary epithelial cells (HMECs) from reduction mammoplasty breast tissue as well as the growth conditions for these cells have been optimized. Experiments have been completed that determined the p53 status in each sample. All samples obtained to date contain functional p53 in response to genotoxic stress.

- b-e. Due to the inconsistencies experienced with regards to the activation of p53 by the ErbB2 protein (discussed in previous summaries) we have not been able to proceed with tasks b-e. Instead, we have focused on the Task 2 objectives. **DISCONTINUED**

Task 2. To “trap” p53 *in vivo* at consensus DNA binding sites after genotoxic stress, and analyze: (i) the heterogeneity of the sites to which p53 is bound compared to the canonical binding site, (ii) the affinity of p53 for a select number of the DNA binding sites recovered, and (iii) the genetic loci and adjacent coding region for novel sites.

- a. Create libraries of DNA fragments to which p53 binds in response to genotoxic stress by cloning the fragments recovered from chromatin immunoprecipitation into a yeast reporter vector. (Months 6-12). **COMPLETED**

- To date three libraries from different cell cultures have been generated. The first library generated was from MCF-10A cells, an immortal but nontransformed mammary epithelial cell line; the second library was generated from the primary human mammary epithelial cells (HMECs), and the third library was generated from the MCF-7 breast cancer cell line. All cells used contain functional p53. The p53-activating treatment was 350 nM adriamycin for 6 h. Adriamycin (doxorubicin) is a commonly used breast cancer chemotherapeutic agent.

- b-c. Use a functional yeast selection system (described in Figure 2) to identify p53 DNA-binding sites that promote transcriptional activation of a reporter gene, and sequence the DNA

fragments recovered from the yeast screen (Months 12-18). **COMPLETED**

- The yeast screen of all 3 libraries generated above has been completed. We have identified more than 100 novel p53 binding sites from the human genome. In addition, we have recovered binding sites of previously identified p53 target genes, including p21 and Mdm2. A representative list is shown in Table 1.
- Test p53-binding DNA fragments identified in (b) in a mammalian cell reporter assay (Months 12-24). **SUPERSEDED/COMPLETED**
- At this point in the study we felt it was more important to analyze the *in vivo* regulation of the genes that the binding sites were regulating instead of using less informative *in vitro* assays to measure transcriptional activation potential. To that end we performed chromatin immunoprecipitation using a p53 specific antibody followed by PCR of the p53 binding site containing DNA fragments recovered to test for *in vivo* binding in **multiple** cell lines (Figures 3 and 4).
- Compare the characteristics and heterogeneity of the newly identified p53 binding sites isolated from mammary epithelial cells subjected to oncogenic stress versus genotoxic stress (Months 24-36). **DISCONTINUED**
- Being that the oncogenic arm of this project was discontinued, we cannot address Task 2e.
- Test the affinity of p53 for the newly identified binding sites by employing an *in vitro* binding assay (Month 12-24). **COMPLETED**
- A select number of DNA fragments isolated from the screen that contained p53 binding sites and resided near genes that we found to be p53-regulated were tested for *in vitro* DNA binding. By using mutational analysis we proceeded to show that p53 is binding specifically to the putative binding site found within the DNA fragments isolated.
- Use genome sequence resources to identify candidate genes that may be directly regulated by p53 binding to the novel sites identified, and verify p53-dependent gene transactivation of these candidate genes through Northern analysis (Months 12-36). **COMPLETED**
- We define a candidate gene as one that is located within 20 kb from the genomic location of the fragment that was isolated by chromatin immunoprecipitation. Candidate gene selection has been performed on all 3 libraries. We have decided that Northern analysis is too time-intensive and instead have changed the validation technique to real-time PCR, which is quicker and more sensitive.
- In addition to the MCF-10A-Neo and MCF-10A-E6 cell lines that were generated earlier in this study (see previous annual summary report), additional primary cells and cell lines were used to validate regulation of putative target genes by p53. These cell lines include the HIp53 cell line, a derivative of the H1299 p53 null lung carcinoma cell line that contains ponasterone-inducible p53, and the isogenic colon carcinoma cell lines HCT116, either p53 null or wild type. The primary cells used to validate the putative target genes were human mammary epithelial cells (HMECs) isolated from reduction mammoplasty breast tissue, and human epidermal keratinocytes (HKs) isolated from the foreskins of newborn males.

- All candidate genes have been identified and validation of four p53-dependently regulated target genes are shown in Figure 5.

KEY RESEARCH ACCOMPLISHMENTS

- Started an human mammary epithelial cell repository with currently over 50 samples from different individuals.
- Completed the generation of all 3 libraries (MCF-10A, HMEC, and MCF-7).
- Completed the yeast screen for all 3 libraries generated.
- Completed *in vitro* DNA-binding assays to test relative affinity of p53 for select novel p53 binding sites recovered.
- Performed chromatin precipitation in multiple cell lines to validate p53 binding to regions of DNA containing the novel p53 binding sites identified.
- Validated endothelin-2, PPM1J, RPS27L, and UBTD1 as novel p53 target genes.

REPORTABLE OUTCOMES

- Poster presentation: Vanderbilt-Ingram Cancer Center Retreat
Nashville, TN
June 6, 2003
title: p53 Signaling in Mammary Epithelial Cells
*received Breast Cancer Program Poster Award
- Poster presentation: American Association for Cancer Research
Advances in Breast Cancer Research
Huntington Beach, CA
October 8-12, 2003
title: Identification of Novel p53 Target Genes in Mammary Epithelial Cells
- Poster presentation: Vanderbilt-Ingram Cancer Center-Meharry Medical School Retreat
Nashville, TN
June 2004
title: p53 Signaling in Mammary Epithelial Cells
- Publication: Jamie Hearnes, Deborah Mays, Kristy Schavolt, Luojia Tang, Xin Jiang, and Jennifer Pietenpol. 2005. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol. Cell. Biol. **25**:10148-10158.

CONCLUSIONS

The overall goal of this research project is to further elucidate p53 signaling pathways in mammary epithelial cells by identifying novel p53 target genes. The results described above show that novel p53 binding sites are being isolated using our experimental approach, and these binding sites are linked to physiologically

relevant p53 target genes. The new p53 binding sites obtained have been mapped to various regions of the human genome, and numerous putative p53 target genes have been identified and validated, including endothelin-2, PPM1J, RPS27L, and UBTD1. Although the goals of the research project have been reprioritized with regards to the oncogenic and genotoxic studies, the data obtained from the genotoxic stress portion is itself very valuable and will lead to a more complete understanding of p53-regulated signaling pathways in mammary epithelial cells and how deregulation of these pathways can lead to breast cancer.

APPENDIX

see attached manuscript

Chromatin Immunoprecipitation-Based Screen To Identify Functional Genomic Binding Sites for Sequence-Specific Transactivators†

Jamie M. Hearnes, Deborah J. Mays, Kristy L. Schavolt, Luojia Tang, Xin Jiang, and Jennifer A. Pietenpol*

Department of Biochemistry, Center for Molecular Toxicology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Received 13 April 2005/Returned for modification 6 June 2005/Accepted 28 August 2005

In various human diseases, altered gene expression patterns are often the result of deregulated gene-specific transcription factor activity. To further understand disease on a molecular basis, the comprehensive analysis of transcription factor signaling networks is required. We developed an experimental approach, combining chromatin immunoprecipitation (ChIP) with a yeast-based assay, to screen the genome for transcription factor binding sites that link to transcriptionally regulated target genes. We used the tumor suppressor p53 to demonstrate the effectiveness of the method. Using primary and immortalized, nontransformed cultures of human mammary epithelial cells, we isolated over 100 genomic DNA fragments that contain novel p53 binding sites. This approach led to the identification and validation of novel p53 target genes involved in diverse signaling pathways, including growth factor signaling, protein kinase/phosphatase signaling, and RNA binding. Our results yield a more complete understanding of p53-regulated signaling pathways, and this approach could be applied to any number of transcription factors to further elucidate complex transcriptional networks.

Regulation of gene expression is required for the maintenance of cellular homeostasis. Deregulation of transcription factor (TF) activities is directly linked to many human diseases, including cancer. It has been estimated that there are ~1,850 TFs encoded within the human genome, and the comprehensive examination of these proteins and their associated regulatory pathways is required to further understand the molecular basis of disease (71). The elucidation of complex transcriptional cellular networks (the identification of TFs, binding sites within the genome, and regulated genes) is an area of intense research focus in the post-human genome-sequencing era.

Many techniques such as subtractive hybridization, differential display, microarrays, and serial analysis of gene expression have been employed to monitor gene expression changes on a genome-wide level. However, a limitation of these methods is that the observed gene expression changes may be due to direct or indirect regulation, making it challenging and time-consuming to delineate the primary gene targets. To this end, chromatin immunoprecipitation (ChIP), the localization of genomic TF binding sites through the cross-linking and immunoprecipitation of an endogenous TF from cells, is a valuable tool used to identify regulatory regions directly bound by a TF in the context of the native chromatin structure. A method widely used to study TF binding is ChIP followed by microarray analysis (ChIP-chip); this method often involves microarray hybridization of the ChIP DNA fragments to specific, known promoter regions or to genomic CpG island regions (35, 41, 47, 55). One critical limitation of some ChIP-chip

analyses is that only segments of promoter regions are analyzed. Thus, other genomic regions that may be bound by TFs (distal regions and enhancers) are excluded from these analyses. By using ChIP and high-density oligonucleotide arrays to analyze Sp1, c-Myc, and p53 binding on chromosomes 21 and 22, investigators found that a majority of the binding sites for these transcription factors do not reside within 1 kb of a CpG island or the 5' exon of a gene (8) and, thus, would have been overlooked using limited promoter fragments on a microarray chip. ChIP-chip involving high-density oligonucleotide arrays is beneficial for whole-genome profiling of TF binding, but currently only single chromosomes are being analyzed, limiting global pathway analyses (19, 48). To circumvent some of these issues, we developed an experimental approach to assay the genome for TF binding sites that link to transcriptionally regulated target genes and used the TF p53 to demonstrate the effectiveness of the method.

The tumor suppressor p53 binds DNA with high affinity in a sequence-specific manner (40) and regulates multiple signaling pathways involved primarily in growth arrest, DNA repair, and apoptosis in response to various cellular stresses (64). To date, more than 100 genes directly regulated by p53 have been identified, leading to a better understanding of the mechanism of p53 tumor suppression (14, 30, 50). However, it is estimated that there are ~1,600 sites to which p53 can bind in the human genome (8). Thus, it seems the genome contains many unidentified p53 target genes, and the identification of these genes will give further insight to complex p53 signaling networks.

We used ChIP to capture p53 binding to genomic DNA on a global level after damage, and the resulting DNA fragments were screened for functional p53 binding and transactivation of a reporter gene using a modified yeast one-hybrid system (69). Our screen yielded not only valuable information regarding the sequence and characteristics of functional p53 binding

* Corresponding author. Mailing address: 652 Preston Research Building, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-6838. Phone: (615) 936-1512. Fax: (615) 936-1790. E-mail: j.pietsch@vanderbilt.edu.

† Supplemental material for this article may be found at <http://mcb.asm.org/>.

sites within the genome but also novel target genes and would be a valuable approach to pursue for any number of TFs.

MATERIALS AND METHODS

Cell culture, treatments, and adenovirus infection. The MCF-10A cells were obtained from the American Type Culture Collection (Manassas, VA), and primary human mammary epithelial cells (HMEC) were purified from normal breast tissue obtained from the Vanderbilt-Ingram Cancer Center Human Tissue Acquisition and Pathology Shared Resource (63); both were cultured as previously described (3). Second-passage primary human epidermal keratinocyte (HK) cells, obtained from the Vanderbilt Skin Disease Research Core, were isolated and grown as previously described (23). The human colorectal carcinoma HCT116 cell lines (6) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. The Hip53 ponasterone A-inducible p53 cell lines (24) were cultured in DMEM supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 600 µg/ml G418 (Mediatech, Herndon, VA), and 400 µg/ml Zeocin (Cayla, Toulouse, France). All cells were grown at 37°C with 5% CO₂ in a humidified incubator. The MCF-10A cells, HMEC, and HCT116 cells were treated with 350 nM adriamycin (ADR); the Hip53 cells were treated with 10 µM ponasterone A; and the HK cells were infected with adenovirus expressing green fluorescent protein (GFP) or p53 (32).

Western analyses. Western analysis was performed as described previously (72) using anti-MDM2 SMP14, anti-p53 PAb1801 (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-p21^{Waf1/Cip1} Ab-1 (Oncogene Research Products, Cambridge, MA) antibodies.

Formaldehyde cross-linking and chromatin immunoprecipitation. Cells were formaldehyde cross-linked in a 1.6% solution for 10 min as described previously (66). For every 2 mg of protein extract processed for ChIP, 10 µg of mouse immunoglobulin G bound to protein A-Sepharose (Pharmacia Biotech, Piscataway, NJ) was used to preclear for 1 h with rocking at 4°C. The extracts were immunoprecipitated with 1 µg of anti-p53 PAb1801 (Santa Cruz) and 1 µg of anti-p53 PAb421 (Oncogene Research Products, Cambridge, MA) or 2 µg of anti-cyclin B1 GNS1 antibodies (Santa Cruz) by rocking overnight at 4°C. For the library generation, a total of 75 mg of MCF-10A cell or HMEC protein lysates was immunoprecipitated, and for the ChIP analyses shown in Fig. 3 and 4, 2 mg of protein lysates was immunoprecipitated from the MCF-10A cells, HMEC, or HK cells. Immunocomplexes were washed eight times as described previously (66), and the protein was degraded in digestion buffer (120 µg/ml proteinase K, 10 mM Tris [pH 7.5], 5 mM EDTA, and 0.5% sodium dodecyl sulfate) at 56°C overnight and then incubated at 65°C for 30 min. The DNA was phenol-chloroform extracted, and ethanol precipitated.

Yeast selection system. The immunoprecipitated genomic DNA was processed using a PCR polishing kit (*Pfu* based; Stratagene, La Jolla, CA), ligated into the HIS3 reporter plasmid, pBM947 (generously provided by M. Johnston; [73]), and amplified by growth in TransforMax EPI300 electrocompetent *Escherichia coli* (Epicenter, Madison, WI). The *Saccharomyces cerevisiae* yeast strain YPH681 containing the pRS314SN vector (51) was transformed as described previously (25) with 100 µg of each pBM947-based library DNA. The cells were plated onto SG media lacking Trp, Ura, and His (SG-Trp-Ura-His) and incubated at 30°C, and colonies were replica plated onto SD-Trp-Ura-His media to screen for false positives.

The pBM947-based library DNA fragments were amplified from the yeast that grew in a p53-dependent manner using a modified yeast colony PCR technique (7). Briefly, 50 cycles of PCR were performed after an initial 4 min at 95°C; each cycle consisted of 1 min at 95°C, 1 min at 56°C, and 1.5 min at 72°C, before a final elongation step of 10 min at 72°C. PCR DNA products were resolved in a 1% agarose gel, stained with ethidium bromide, purified, and sequenced.

RNA preparation and reverse transcription. mRNA was harvested from the Hip53 and HK cells as previously described (66). Total RNA was harvested from the HCT116 cells using the Aurum total RNA minikit (Bio-Rad Laboratories, Hercules, CA). Reverse transcription of 100 ng of poly(A) RNA from the Hip53 and HK cells and 250 ng of total RNA from the HCT116 cells was performed using the TaqMan reverse transcription reagent kit (Applied Biosystems, Foster City, CA).

PCR amplification. The ChIP PCR amplifications for CDKN1A (p21) site 1 and DDB2 (p48) were performed in 16.6 mM (NH₄)₂SO₄, 0.67 mM Tris (pH 8.8), 6.7 mM MgCl₂, 10 mM β-mercaptoethanol, 10% dimethyl sulfoxide, 1.5 mM nucleotides, and 1.25 U of *Taq* polymerase (Fig. 3). A total of 175 ng of each primer was used per 25-µl reaction mixture. The ChIP PCR amplifications for EDN2, PPM1J, RPS27L, UBTD1, PDGFC, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were performed in 10 mM Tris (pH 9.0), 50 mM KCl,




FIG. 1. Analysis of p53, MDM2, and p21 protein levels in MCF-10A cells and HMEC after ADR treatment. Shown is Western blot analysis of p53, MDM2, and p21 protein harvested from MCF-10A and primary HMEC that were not treated (−) or treated (+) with ADR (350 nM) for 8 h.

0.1% Triton X-100, 0.5 mM MgCl₂, 0.25 mM nucleotides, and 1.25 U of *Taq* polymerase (Fig. 3). Each primer was used at 0.4 µM per 25-µl PCR mixture. Primer sequences and PCR conditions are provided in Table S1 in the supplemental material.

Quantitative real-time PCR (Q-RT-PCR) was performed for p53 binding analyses (Fig. 4) using chromatin-immunoprecipitated DNA (described above) and normalized to a genomic template that was cross-linked and sonicated, but not immunoprecipitated. Q-RT-PCR was performed for the gene expression analyses (Fig. 5) using 2 ng of reverse-transcribed mRNA or 5 ng of reverse-transcribed total RNA template. Q-RT-PCR SYBR-Green Supermix (Bio-Rad) reaction mixtures contained 200 nM of each primer and were run on an iCycler thermal cycler (Bio-Rad). Primers were designed using the Beacon Designer software (Bio-Rad). Target gene expression was normalized to GAPDH, and changes were calculated relative to control samples. For primer sequences and PCR conditions see Table S1 in the supplemental material.

RESULTS

Library generation and yeast screen. We used primary HMEC and the immortal, nontransformed MCF-10A human mammary epithelial cell line to generate libraries of DNA fragments that p53 bound after the cells were treated with the genotoxic agent ADR. We selected immortal, nontransformed and primary cells to avoid genetic and epigenetic chromatin alterations observed in transformed cells. To verify p53 signaling in these systems, cells were treated with ADR (350 nM) for 8 h and analyzed for changes in p53, MDM2, and p21 protein levels. ADR treatment led to increased p53 levels in HME and MCF-10A cells as well as elevation of the downstream targets p21 and MDM2 (Fig. 1). Of note, under this treatment condition, both the HMEC and the MCF-10A cells underwent cell cycle arrest as opposed to apoptosis (data not shown).

To isolate DNA fragments that p53 bound after ADR treatment, the MCF-10As were treated with ADR for 5 h and the HMEC for 4, 8, 16, and 24 h and both cell types were cross-linked with formaldehyde and lysed (the HMEC lysates were pooled). The lysates were sonicated to shear the chromatin into ~600- to 1,000-bp fragments. The chromatin was immunoprecipitated using p53-specific antibodies, the cross-linking was reversed, and the DNA fragments were purified and cloned into the pBM947 yeast expression vector upstream of a minimal promoter that controls the expression of the HIS gene. The pBM947-based library of putative p53-binding DNA fragments was transformed into an auxotrophic histidine-deficient yeast strain with a galactose-inducible yeast expression vector containing the human p53 gene (pRS314SN). Yeast transformants containing both the pRS314SN and pBM947 vectors were able to grow on galactose-containing, histidine-deficient media if




FIG. 2. Yeast selection system. The candidate upstream activating sequences (UAS) recovered from ChIP were cloned into the pBM947 reporter vector containing the HIS3 gene under the control of a basal GAL1 promoter and a URA1 marker. The pBM947-based library was transformed into an auxotrophic His-deficient yeast strain containing the pRS314SN vector, which expresses a galactose-inducible human wild-type p53 and a TRP1 marker. Yeasts containing both the vectors were grown on galactose-containing, histidine-deficient media (SG-Trp-Ura-His) to assay for the ability of p53 to bind to the potential UAS in the pBM947 vector and activate transcription of the HIS3 gene. Replica plating of all clones on glucose-containing, histidine-deficient media (SD-Trp-Ura-His) was performed to rule out false-positive clones. The clones that grew in the presence of glucose were considered false positive, and only the clones that grew on galactose, and presumably in a p53-dependent manner, were analyzed further. A clone containing a fragment of the p21 promoter encompassing site 1 is indicated as an example of a positive result.

the expressed p53 bound to the human genomic DNA fragment in the pBM947 vector and activated transcription of the HIS3 gene. To rule out false-positive clones that grew in a p53-independent manner, we also replica plated all clones on glucose-containing, histidine-deficient media. The clones that grew in the presence of glucose and, thus, in the absence of p53, were considered false positives and not further analyzed (Fig. 2).

For the MCF-10A library, $\sim 3.2 \times 10^6$ yeast transformants were screened, and 187 clones grew in a p53-dependent manner. After sequencing, 51 nonredundant sequences were identified. For the HMEC library, $\sim 1.7 \times 10^6$ yeast transformants were screened, resulting in 74 nonredundant positive clones that grew in a p53-dependent manner. A control library generated from immunoprecipitation of identically processed lysates using an isotype-matched antibody (cyclin B1) was also screened to determine the level of nonspecifically bound DNA fragments that contained sequences conforming to the p53 consensus. There was a sevenfold reduction in the number of colonies from the control library that grew in a p53-dependent manner; of those only four clones had putative p53 binding sites as identified by the p53MH algorithm (34). Thus, the

majority of the DNA fragments present in the experimental libraries resulted from specific interactions with p53.

Analysis of genomic DNA fragments for p53 consensus binding sites and the identification of candidate target genes. The DNA fragments isolated from the combined screening of the HMEC and MCF-10A cell libraries were analyzed for the presence of p53 consensus DNA binding sites using the p53MH algorithm (34). The canonical p53 binding site consists of two repeats of the 10-bp sequence PPPCWWGYYY (where P = A/G, W = A/T, and Y = T/C) separated by a 0- to 13-bp spacer region, (15). Of the fragments isolated from the HMEC and MCF-10A cell libraries, 99% contained putative p53 binding sites. A representative list is shown in Table 1; for the additional sites see Table S2 in the supplemental material.

The sequences of the library DNA fragments were aligned with the human genome using the BLAST search of the Human Genome Resources Database from the National Center for Biotechnology Information (NCBI) website, and candidate target genes were selected for validation. The criterion for selection was any known or predicted gene with the start of exon 1 within 20 kb upstream or downstream of where the sequence of the DNA fragment aligned. This criterion was chosen because approximately 99% of known p53 binding sites occur within 20 kb of the regulated gene. However, if the library DNA fragment aligned to an intron of a gene, regardless of the distance between the alignment and the start of exon 1, the gene was included as a candidate. After analyzing the DNA fragments generated from both libraries, ~ 100 candidate target genes were identified, including both known and predicted genes. The chromosomal location, the location of the binding site in relation to the known or candidate target gene, and the distance of the binding site from the beginning of exon 1 of the associated known or candidate gene are shown (Table 1; see Table S2 in the supplemental material). The genes identified from the screen encode proteins involved in numerous cellular pathways including protein kinase/phosphatase signaling, protein transport, growth factor signaling, RNA binding, and chromatin remodeling. Numerous predicted genes with unknown functions were also identified. Of note, less than 25% of the DNA fragments aligned to regions of the genome that did not contain known or predicted genes within the criterion range. We recovered binding sites that were both 5' to the candidate target genes and intronic, and, interestingly, we also recovered p53 binding sites 3' of putative target genes. In addition to novel genomic p53 binding sites, the library screen (LS) yielded multiple known p53 binding sites. For instance, both of the p53 binding sites from the CDKN1A (p21) promoter were isolated (17), as well as the p53 binding sites from the MDM2 (77) and DDB2 (68) genes. The recovery of known p53 response elements that regulate key p53 target genes validated our method and demonstrates that the screen selects for functionally relevant binding sites and physiologically important target genes.

Analysis of *in vivo* binding of p53 to novel consensus binding sites. To further validate p53 binding to the novel binding sites recovered from the library screen, we generated pools of DNA fragments from ChIP of ADR-treated HMEC and MCF-10A cells and primary cultures of HK cells. The latter were included in our analyses to compare binding results across primary cell types from two human tissues. The ChIP DNA was used as a

TABLE 1. Representative p53 consensus binding sites and candidate target genes

Gene or DNA fragment ^a	GenBank accession no.	Description	p53 binding site ^b	Match ^c	Location ^d	Distance from exon 1 (kb)	Chromosome location ^e
CDKN1A	NM_078467	Cyclin dependent kinase inhibitor 1A (p21, Cip1)	PPPCWWGGYY-x-PPPCWGWYYY ^e	5'	2.2	6p21.2	
CDKN1A	NM_078467	Cyclin dependent kinase inhibitor 1A (p21, Cip1)	caACATGTTg-0-GGACATGTTTC	5'	1.3	6p21.2	
MDM2	NM_002392	Murine double minute 2, p53 binding protein	AGACT ^f gG-Ca-0-tGtCTgG-Ca	<1	12q14.3-15		
DBB2	NM_000107	Damage-specific DNA binding protein 2 (p48)	GGCAAA-GCC-1-GGGCATGTTT	<1	11p12-p11		
AKAP6	NM_004274	A kinase anchor protein 6	AGACATGCC-0-AAACATGTTCT	20	Intron 1	16	14q12
FLJ32800 ^f	NM_152647	Predicted	AGGCATGTTCT-0-GGACATGTTT	20	Intron 2	4	15q21.1-2
MDS009 ^f	NM_020234	DTWD1 (DTW domain containing 1)	GGACATGCC-0-GGACAAAGCCT	20	NA	2.5	15q21.2
H955	NA ^g	NA	AGACATGCC-0-GGGCATGCTT	20	NA	NA	13q14.3
H1160	NA	NA	AGACATGCC-0-GGGCATGCTT	20	NA	NA	1q25.3
RHOC ^h	NM_175744	Ras homolog gene family product, member C	GAACATGCC-0-GAGCAAGCCC	20	Intron 2	3	1p13.1
MGC19531 ^h	NM_005167	PPMLJ (protein phosphatase 1J, PP2C domain containing)	AGACATGCC-2-AGACATGCC	20	Intron 14	11	1p13.1
PP2R3A	NM_002718	Protein phosphatase 2, regulatory subunit B, alpha	GGACATGCC-0-GGGCTTGCTC	20	Intron 14	176	3q22.1
TMEM30A	NM_018247	Transmembrane protein 30A	AGACATGCC-0-GGGCTTGCTC	20	Intron 1	12	6q14.1
UBTD1 ^h	NM_024954	Ubiquitin domain containing 1	tGACAAGTCT-0-GGGCTTGCTC	19	Intron 1	50	10q24.1-2
ANKRD28	NM_020349	Ankyrin repeat domain 2	GGGCATGTTg-0-GGGCATGTC	19	NA	22	10q24.2
H1026	NA	NA	GGGCATGCC-0-GGACATGTC	19	NA	NA	5p15.3
LOC441968	XM_497787	Similar to extensin-like protein	GGGCATGCC-3-0-GGACATGTC	19	NA	6	21q22.3
PDGFC	NM_016405	Platelet-derived growth factor, isoform C	GGGCATGTTg-0-AGACTGCCC	19	Intron 4	200	4q32
ANKRD11	NM_013275	Ankyrin repeat domain protein 11	AGACATGCC-0-tGGCATGTC	18	Intron 1	50	16q24.3
EDN-2	NM_001956	Endothelin-2	ctGCAAGCCC-0-GGGCATGCC	18	Intron 3	2	1p34
FLJ12484 ^h	NM_022767	ISG20L1 (interferon-stimulated exonuclease 20 kDa-like 1)	5'	<1	15q26.1		
ISG20 ^h	NM_0022201	Interferon-stimulated exonuclease, 20 kDa	ccACATGCC-0-GGGCAAAGCCC	18	17	15q26	
LOC388171 ^h	XM_375647	Predicted	tGGCATGTC-11-cAACATGCC	3'	17	15q26.1	
PTPN14	NM_005401	Protein tyrosine phosphatase, nonreceptor type 14	AAACATGTTg-0-cAACATGCC	18	Intron 3	115	1q32.2
VT1A	NM_145206	Vesicle transport through interaction with t-SNARE homolog 1A	caACATGTC-0-tGGCATGTC	18	270	10q25.2	
H1634	NA	NA	tGGCATGTC-11-cAACATGCC	18	NA	NA	12q23.3
C9ORF88	XM_497077	Chromosome 9 open reading frame 88 product	tGGCAAGCag-0-AGGCTTGTTC	17	Intron 1	3	9q34.11
RB1M19	NM_016196	RNA binding motif protein 19	GAACATGTC-0-GGGCATGTT ^g	17	Intron 24	127	12q41.3-21
RPS27L	NM_015920	Ribosomal protein S27-like (40S ribosomal protein S27, isoform)	GGGCATGTTg-0-tGACTTGGCC	17	Intron 1	2	15q22.2
SMARCC1	NM_003074	SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin	GGGCATGta ^h g-4-AtGCCtGTaa	14	Intron 7	65	3p23-21

^a The four items above the space are known p53 target genes; those below the space are products of candidate genes, except for H955, H1160, H1026, and H1634, which are DNA fragments that aligned to areas of the genome that did not contain any candidate genes within the criterion range. Items with the same symbol (f, g, §, or ¶) are products of multiple candidate genes identified within the criterion range of a single binding site.

^b Lowercase letters indicate consensus binding site mismatches.

^c Number of base pairs (out of 20) in the putative p53 binding site that match the consensus binding site.

^d Location of the p53 binding site in relation to the known/candidate target gene.

^e p53 consensus binding site, where P = purine (A/G), W = A/T, Y = pyrimidine (C/T), and x = 0- to 13-bp spacer region.

^f Location of the candidate target gene or binding site (if a candidate gene was not identified).

^g NA, not applicable.




FIG. 3. Analysis of p53 *in vivo* binding to consensus binding sites. Three sets each of MCF-10A cells, HMEC, and HK cells were identically processed: one set was treated with ADR (350 nM for 5 h) and formaldehyde cross-linked (ADR +, X-L +), another set was not treated with ADR and was formaldehyde cross-linked (ADR -, X-L +), and a final set was treated with ADR and not formaldehyde cross-linked (ADR +, X-L -). The DNA for PCRs was derived from p53-specific and cyclin B1-specific immunoprecipitations (IP) and amplified using primers flanking the p53 response elements in genes encoding the indicated proteins. PCRs were resolved with polyacrylamide gel electrophoresis, and the gels were stained with ethidium bromide. The cyclin B1-specific IPs were included to assess any DNA fragments purified from cross-linked lysates nonspecifically. Input +, genomic input; input -, water control. PCR results with primers directed to the coding region of GAPDH serve as a control for nonspecific DNA IP by p53-specific antibodies.

template for PCR amplification of the genomic regions containing response elements obtained from the library screen. All of the genomic binding sites shown in Table 1 were present in these replicate pools of DNA fragments, and representative ChIP-PCR results from the HMEC, MCF-10A cell, and HK cell lysates are shown in Fig. 3. The binding sites shown were chosen due to their differential locations with regard to exon 1 of the associated candidate gene, as well as the varied cellular functions of the target genes. Response elements in CDKN1A (p21) and DDB2 (p48) genes, known p53 target genes, as well as the binding sites associated with EDN-2, PPM1J, RPS27L, and PDGFC genes were bound by p53 before ADR treatment as well as after ADR treatment in all cell systems analyzed. The UBTD1 gene-associated p53 response element was bound by p53 before ADR treatment in the MCF-10A cells, but binding was not detectable in the HMEC and HK cells. However, binding of p53 to the UBTD1 gene response element was detected after ADR treatment in all cell lines analyzed.

To analyze the specificity of p53 binding to the sites that we recovered from the libraries, we performed Q-RT-PCR on ChIP DNA fragments using primers specific to regions containing the binding sites identified from our screen, as well as other putative binding sites within 20 kb upstream or downstream of the start of exon 1 identified by the p53MH algorithm (34), but not recovered from our screen (Fig. 4). Cells were treated as outlined in the Fig. 3 legend, and the ChIP DNA was analyzed by Q-RT-PCR. All samples were normal-

ized to a sample of genomic DNA from treated, cross-linked, and sonicated lysates that were not chromatin immunoprecipitated, and the results are shown as percentages of that input. Schematics showing the structure of each gene and the locations of binding sites that were either identified through the library screen, previously reported, or identified using the p53MH algorithm are shown in the right panels of Fig. 4. Also shown for these sites is their conservation across species. For CDKN1A, four potential p53 binding sites were analyzed along with the two binding sites that were recovered from the library screen. These two binding sites are the two previously reported p53 binding sites for the CDKN1A gene (16). Significant binding of p53 was observed only at both of the previously reported sites. Of note, all of the algorithm-derived, potential binding sites matched the consensus to a higher degree than the RS/LS2 site (12 of 20); however, none of the potential sites exhibited more binding than this site. For EDN-2, five potential binding sites, including the one site isolated from our screen, were analyzed. Binding was greatest at the intronic site recovered from the library screen that fit the consensus to a high degree, 18 of 20 bp. Interestingly, this site was not one of the two sites localized nearest to exon 1. For the PPM1J gene, we analyzed the site recovered from our library as well as three other potential p53 binding sites. The only sample that showed appreciable binding was that isolated from the library screen. Interestingly, both the EDN-2 and PPM1J sites isolated from the library screen are not as well conserved (only in rats) as the other binding sites analyzed for these genes. For the RPS27L gene, two potential binding sites and the site isolated by the screen were analyzed, and for the PDGFC gene, three potential sites were analyzed as well as the library-generated site. In both genes, p53 binding was seen predominantly in the library-generated sites and was observed both before and after treatment with ADR. Although several primer sets were used, the UBTD1 gene could not be reliably analyzed by Q-RT-PCR.

p53-dependent regulation of candidate target gene mRNA.

To determine if p53 binding to response elements correlated with p53-dependent transcription for the genes shown in Fig. 3, we performed Q-RT-PCR analysis on RNA isolated from three cell model systems: (i) the isogenic pair of HCT116 p53^{+/+} and p53^{-/-} cells (6) treated with ADR, (ii) an inducible H1299 cell line in which p53 expression was under the control of the ecdysone promoter and induced by ponasterone A addition (HIp53), and (iii) primary cultures of HK cells infected with a p53- or GFP-expressing adenovirus (Fig. 5).

p21 and p48 are encoded by known p53 target genes; they function in cell cycle arrest and DNA repair (64), respectively, and were included in the analysis for comparison of expression between novel and known targets. p21 was induced by p53 in all cell lines examined, and p48 was regulated in only two of the three cell lines. The EDN-2 gene, a gene encoding a secreted vasoactive peptide (ET-2) with a proposed role in cell survival after hypoxia in breast epithelial cells (2, 27), was elevated in a p53-dependent manner in all cell types analyzed. PPM1J, a member of the protein phosphatase type 2C family (52), was also induced in a p53-dependent manner in all cell types. As shown in Table 1, another gene, the RHOC (ras homolog gene family, member C protein [9]) gene, is located in close proximity to the PPM1J gene and the associated p53 binding site. However, p53-dependent regulation of the RHOC gene was




FIG. 4. Comparative analysis of p53 binding to sites in promoter regions of known and candidate target genes. In the left panels, four sets of HMEC were processed as follows: one set was treated with ADR (350 nM for 5 h), formaldehyde cross-linked, and immunoprecipitated with a p53 antibody (solid bars); another set was treated with ADR, formaldehyde cross-linked, and immunoprecipitated with a cyclin B1 antibody (open bars); a third set was treated with ADR, not formaldehyde cross-linked, and immunoprecipitated with a p53 antibody (dotted bars); and a final set was formaldehyde cross-linked but not treated with ADR and then immunoprecipitated with a p53 antibody (gray bars). Quantitative real-time PCR was performed, and each sample was normalized to the same genomic DNA that was isolated from cells that were cross-linked and processed the same with the exception that the immunoprecipitation step was not performed. The binding sites shown are those that were recovered from the library screen (LS), those that were previously reported in the literature (RS), and those that were potential binding sites found by gene analysis using the p53MH algorithm (PS). The base pair match of the binding site to the p53 consensus is shown in parentheses. The results, shown as percentages of input DNA, are from at least three independent experiments, with the error bars representing standard deviations. The right panels show schematics of the genomic structure and localization of known and putative p53 binding sites analyzed. The bar shading indicates species conservation as indicated. Exons are indicated with an E followed by the exon number in either an open box or a shaded box (representing the terminal exon). The sequences of the binding sites present in the regions analyzed are shown, and in parentheses the distances of the binding sites from the start of exon 1 are given.




FIG. 5. p53-dependent regulation of representative candidate target gene expression. The isogenic pair of HCT116 p53^{+/+} and p53^{-/-} cells were treated with ADR (350 nM) for 0, 6, 12, and 24 h; the HIP53 cells (p53) and corresponding vector control cell line (Ø) were treated with ponasterone A (10 μ M) for 24 h, and the HK cells were infected with a GFP- or p53-expressing adenovirus for 30 h. Total RNA from HCT116 cells and mRNA from HIP53 and HK cells was purified and reverse transcribed and quantitative real-time PCR performed. The samples were normalized to GAPDH, and the results are presented as changes relative to either the 0-h HCT116 p53^{+/+} sample (left panel), the HIP53 vector control cells treated with ponasterone (middle panel), or the HK cells infected with a GFP-expressing adenovirus (right panel). The results are the means of three independent experiments (MCF-10A cells and HMEC) or duplicate experiments (HK cells), with error bars representing the standard deviations. Note that the y axes are set to 7.0 with the exceptions of the left and middle panels for the CDKN1A gene and the left and right panels for the EDN-2 gene.

not observed (data not shown). The RPS27L gene, a gene similar to the 40S ribosomal subunit S27 gene (65, 78), was also regulated in a p53-dependent manner in all three systems analyzed. Similar to the p48 gene, the UBTD1 gene (9, 65) was regulated by p53 in two of the three cell systems analyzed. Another gene, the ANKRD2 (ankyrin repeat domain 2 protein [39]) gene, is located in close proximity to the UBTD1 gene and the p53 binding site; however, we did not observe p53-dependent regulation of the ANKRD2 gene (data not shown). The gene encoding PDGFC, a member of the PDGF growth

factor family (44), was not regulated in a p53-dependent manner in any of the cell systems used in this study. There were no open reading frames within 20 kb upstream or downstream of the binding site, thus ruling out the possibility that a neighboring gene within this distance was the target. Our analysis of PDGFC provides additional evidence that p53 binding does not necessarily equate to transcriptional regulation. In sum, the genes analyzed can be divided into three categories: those that were p53 regulated in all cell systems (CDKN1A, EDN-2, PPM1J, and RPS27L genes), those that were regulated in a subset (DDB2 and UBTD1 genes), and those that were bound but not regulated by p53 under the conditions analyzed in this study (PDGFC gene).

DISCUSSION

Many studies focusing on target gene identification have used techniques that only provide information about gene expression but do not yield information regarding the direct/indirect nature of gene regulation. Of those studies that analyze TF binding, (e.g., ChIP-chip), typically only promoter regions are used in the analyses, excluding other genomic regions potentially bound by TFs (distal regions and enhancers). One advantage of the screen used in the present study is the ability to identify functional TF binding sites throughout the genome, not only in promoter regions, similar to a recent ChIP-based screen performed by Impey et al. (36). Our analysis of binding site locations in the human genome in relation to putative target genes showed that a majority of p53 binding sites were localized to the introns of candidate target genes, not to 5'-proximal promoters. This coincides with the prevalence of intronic binding sites in many known p53 target genes, including the MDM2 and GADD45 genes (11, 77). This intronic-binding-site characteristic is not unique to p53. When Martone et al. studied NF- κ B binding to the human genome using ChIP followed by a genomic microarray of human chromosome 22, they also found a significant proportion of binding occurred in the intronic areas (48). We also recovered a binding site that was 3' of the candidate target PPM1J gene, the first report of a functional 3' binding site for a putative p53 target gene. These data reiterate the importance of analyzing the whole genome, not only proximal promoters, when searching for functional TF regulatory regions. A further advantage of using the ChIP-based screen described herein over a screen of random genomic DNA is that the former identifies binding sites that a TF "is" bound to at a specific time under a certain physiological condition versus a screen of random genomic DNA that only identifies fragments of DNA that a TF "can" bind to, but may not under any physiologically relevant condition. Under the conditions used to generate the libraries of DNA fragments for our screen, ADR treatment of breast epithelial cells, we recovered three known p53 target genes, the functions of which are consistent with the biological end point we observed. It was not anticipated that the screen would identify all known p53 target genes given that the ChIP performed would select only for the genomic loci that p53 was bound to after ADR treatment.

After analyzing the characteristics of the binding sites recovered in this study, we found that, for the MCF-10A library, 45% of the putative binding sites matched the consensus site at

greater than or equal to 17 of 20 bp, and, for those binding sites, 56% had spacer regions of 2 bp or less. For the HMEC library, 83% of the putative binding sites obtained from the positive clones matched the consensus site at greater than or equal to 17 of 20 bp, and for those binding sites, 83% had spacer regions of 2 bp or less. In addition, ~25% of the isolated fragments had p53 binding sites that fit the p53 consensus perfectly (a match of 20 of 20 bp). Preceding this study only two p53 target genes had been identified with binding sites that fit the consensus at 20 of 20 bp, the DDB2 and type IV collagenase genes (4, 68). Interestingly, the binding site of one of the novel target genes identified by our screen, the PPM1J gene, is a 20- of 20-bp fit to the canonical binding sequence. Although a majority of the binding sites recovered were in close concordance with the consensus binding site, highly degenerate response elements were also identified. For example, the highly degenerate, but physiologically relevant, second p53 response element in p21 (17), which matches the consensus at only 12 of 20 bp, was isolated. In addition, we observed trends involving the lengths of the binding site spacer regions; a majority of the novel binding sites contained a 0- to 2-bp spacer, indicating that p53 binding to genomic DNA under the conditions assayed was more prevalent at sites that have short spacers or none at all. This observation is supported by a previous finding showing that artificially constructed binding sites containing a 4- or 14-bp spacer have greater-than-90%-reduced activity in a yeast reporter assay system than did the same binding site with a 0-bp spacer (69). Our data also correlate with the characteristics of known p53 target gene binding sites, ~70% of which contain 0- to 2-bp spacers (54).

The *in vivo* specificity of the binding sites recovered from our screen was evidenced by the fact that p53 preferentially bound to these sites even though some of the p53MH algorithm-derived binding sites in the region matched the consensus to an equal or higher degree, were closer to exon 1, or were more conserved. Our results show that p53 binding is not solely dependent upon the fit of the binding site to the consensus, and matching the consensus is not sufficient for p53 binding. Other factors could also play a role in dictating binding site specificity, including the sequence context surrounding the binding site as well as access of p53 to the DNA due to chromatin structure. In addition, posttranslational modifications of the p53 protein, such as phosphorylation and acetylation, and cofactor interactions could affect its DNA binding characteristics (5, 12).

In our analyses, we highlighted four novel p53 target genes involved in diverse signaling pathways, each potentially contributing to our further understanding of p53 biology. EDN-2 is a member of the endothelin family, first discovered as potent vasoactive peptides (2). The protein ET-2 can function as an autocrine survival factor in response to hypoxia in breast cells (27) and as a macrophage cell chemoattractant (28). The identification of the EDN-2 gene as a p53 target gene, in combination with the findings that p53 can regulate other genes involved in growth factor and survival signaling, such as genes encoding HB-EGF (heparin-binding epidermal growth factor) (20), EGFR (epidermal growth factor receptor) (46), HGF (hepatocyte growth factor) (49), TGF- α (transforming growth factor alpha) (61), and, most recently, p53CSV (p53-inducible cell survival factor) (53), strongly suggests that, in addition to

the well-defined role p53 plays in promoting cell viability through cell cycle arrest and DNA repair, the protein can also play an active role in initiating survival pathway signaling in the cell.

The identification of the gene encoding PPM1J, a PP2C family member, as a p53 target gene contributes to the growing list of phosphatase genes regulated by p53, including the PTEN (62), DUSP5 (70), PAC1 (75), and WIP-1 (21) genes. Interestingly, WIP-1, also known as PPM1D, is also a family member of the protein phosphatase 2C family and inhibits UV-induced apoptosis by negatively regulating the p38 mitogen-activated protein kinase-p53 signaling pathway (67). The exact role of PPM1J in human cells is not known, but its gene is conserved in mice and rats, and the murine homolog, PP2CZ, can associate with the ubiquitin-conjugating enzyme 9 (Ubc9). Ubc9 is involved in the sumoylation of protein substrates, and the PP2CZ-Ubc9 interaction is enhanced in the presence of the small ubiquitin-related modifier (SUMO) protein (38). These observations suggest that PPM1J may be involved in the regulation of sumoylation processes in the cell. Since sumoylation regulates the localization and activity of proteins involved in numerous cellular functions including transcription, DNA repair, and chromatin structure (26), the involvement of p53 in the regulation of the gene could dramatically impact cellular dynamics.

Another gene identified as a p53 target in this study was the RPS27L gene (65, 78). Although the function of human RPS27L is unknown, data show that ARS27A, one of the three ribosomal protein S27 homologues in *Arabidopsis thaliana*, is involved in genotoxic stress-dependent mRNA degradation. Loss of ARS27A gene expression in *Arabidopsis thaliana* leads to hypersensitivity to methyl methanesulfonate treatment that is accompanied by inhibition of seedling growth and formation of tumor-like structures instead of auxiliary roots. The ARS27A protein is not required for translation; instead it is needed for the degradation of damaged mRNA in response to UV (56). It is possible that the RPS27L gene could play a similar role in humans. Recently, another p53 target gene, encoding MCG10, a KH-domain containing RNA-binding protein, has been identified (80). These genes link p53 to pathways involved in RNA binding and regulation, and this aspect of p53 function has yet to be explored.

As mentioned previously, we identified candidate target genes whose functions are currently unknown. One such example is the UBTD1 gene, a gene encoding a protein containing an ubiquitin domain (9, 65). p53 is well linked to the ubiquitination pathway through its transcriptional regulation of four ubiquitin ligases, MDM2 (31, 42), COP1 (13), Siah1b (22), and Pih2 (43). However, based on the limited information available for UBTD1, we cannot speculate on the role its gene may play in p53 signaling. Also, the UBTD1 gene is regulated in only a subset of the cell model systems assayed. This example illustrates the discriminatory nature of p53 target gene selectivity, which is dependent on various factors including, but not limited to, the cell types analyzed and the specific signals leading to p53 activation.

A number of candidate target genes identified in our screen were not regulated in a p53-dependent manner, although we validated binding to DNA regions adjacent to the genes through additional ChIP analyses (the PDGFC gene being the example shown). There are many potential reasons for this

observed lack of transcriptional regulation. For instance, it is likely that p53-dependent expression of these genes could be tissue/cell type specific and/or specific to the type of cellular stress activating p53, which has been reported from other studies analyzing the regulation of p53-inducible genes (76, 79). In addition, it is possible that p53 regulates antisense or noncoding RNAs not analyzed in this study. The transcriptome consists of an RNA population that is larger than what would be expected if only taking into account the protein-coding transcripts (10, 37, 57, 60). By analyzing a subset of the novel transcripts in the transcriptome, it was concluded that they represent RNA that is most likely not protein encoding, and some of the transcripts even had an orientation that was antisense to a known protein-coding region (37). In addition, when Cawley et al. examined TF (Sp1, cMyc, and p53) binding on chromosomes 21 and 22 using high-density oligonucleotide arrays, they found that many binding sites were significantly correlated with noncoding RNAs. They concluded that there are about the same number of protein-coding and noncoding genes in the transcriptome and that these two types of genes can be bound and regulated by common TFs (8). Alternatively, p53 occupancy at certain response elements (without measurable gene regulation) may affect chromatin remodeling in select regions of the genome. It is well established that p53 is required for global genomic repair in the nucleotide excision repair pathway following DNA damage (29). Further, p53-dependent global chromatin relaxation occurs in response to low doses of UV that are not high enough to activate the protein's activity as a transcription factor (45, 58, 59, 74). Also, p53 can impact histone H3 posttranslational modifications under normal cellular conditions (1). These data suggest that p53 can play a role in chromatin relaxation and remodeling.

The lack of identification of p53-repressed genes was not surprising, given that the majority of p53-repressed genes lack a consensus p53 binding site (33) and thus would not have been isolated. Also, we did not identify DNA fragments adjacent to genes involved in apoptotic signaling, consistent with our finding that ADR (350 nM) does not induce apoptosis in HMEC and MCF-10A cells and the findings of other studies showing lack of constitutive p53 binding to proapoptotic genes (18, 66).

The screen presented herein can be used to directly identify novel genes regulated by other TFs of interest (that maintain activity in yeast) on a genome-wide scale. Comparative analyses of functional binding sites occupied by transcriptional activators under various cellular conditions can be performed with this type of screen. As more genomic, proteomic, and bioinformatic advances are made, the hope is that ChIP-based methods will allow further characterization of protein complexes and chromatin structure at binding sites identified by methods such as those described in this study.

ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health grants (CA70856, CA105436 [J.A.P.], ES00267, and CA68485 [Core Services]), The Komen Foundation, and a U.S. Army grant (DAMD17-02-1-0605 [J.M.H.]).

We thank the members of the Pietenpol laboratory for helpful discussions and critical reading of the manuscript.

REFERENCES

- Allison, S. J., and J. Milner. 2003. Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy. *Cancer Res.* **63**:6674–6679.
- Bagnato, A., and P. G. Natali. 2004. Targeting endothelin axis in cancer. *Cancer Treat. Res.* **119**:293–314.
- Band, V., and R. Sager. 1989. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. *Proc. Natl. Acad. Sci. USA* **86**:1249–1253.
- Bian, J., and Y. Sun. 1997. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. *Mol. Cell. Biol.* **17**:6330–6338.
- Bode, A. M., and Z. Dong. 2004. Post-translational modification of p53 in tumorigenesis. *Nat. Rev. Cancer* **4**:793–805.
- Bunz, F., P. M. Hwang, C. Torrance, T. Waldman, Y. Zhang, L. Dillehay, J. Williams, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. *J. Clin. Investig.* **104**:263–269.
- Burke, D., D. Dawson, and T. Stearns. 2000. Yeast colony PCR protocol, p. 141–142. In D. Burke, D. Dawson, and T. Stearns (ed.), *Methods in yeast genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Cawley, S., K. Bekirano, H. H. Ng, P. Kapranov, E. A. Sekinger, D. Kampa, A. Piccolboni, V. Sementchenko, J. Cheng, A. J. Williams, R. Wheeler, B. Wong, J. Drenkow, M. Yamanaka, S. Patel, S. Brubaker, H. Tammana, G. Helt, K. Struhl, and T. R. Gingeras. 2004. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. *Cell* **116**:499–509.
- Chardin, P., P. Madaule, and A. Tavitian. 1988. Coding sequence of human rho cDNAs clone 6 and clone 9. *Nucleic Acids Res.* **16**:2717.
- Chen, J., M. Sun, S. Lee, G. Zhou, J. D. Rowley, and S. M. Wang. 2002. Identifying novel transcripts and novel genes in the human genome by using novel SAGE tags. *Proc. Natl. Acad. Sci. USA* **99**:12257–12262.
- Chin, P. L., J. Momand, and G. P. Pfeifer. 1997. *In vivo* evidence for binding of p53 to consensus binding sites in the *p21* and *GADD45* genes in response to ionizing radiation. *Oncogene* **15**:87–99.
- Coutts, A. S., and N. B. La Thangue. 2005. The p53 response: emerging levels of co-factor complexity. *Biochem. Biophys. Res. Commun.* **331**:778–785.
- Dornan, D., I. Wertz, H. Shimizu, D. Arnott, G. D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, and V. M. Dixit. 2004. The ubiquitin ligase COP1 is a critical negative regulator of p53. *Nature* **429**:86–92.
- El-Deiry, W. S. 1998. Regulation of p53 downstream genes. *Cancer Biol.* **8**:345–357.
- El-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. *Nat. Genet.* **1**:45–49.
- El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. *WAF1*, a potential mediator of p53 tumor suppression. *Cell* **75**:817–825.
- El-Deiry, W. S., T. Tokino, T. Waldman, J. D. Oliner, V. E. Velculescu, M. Burrell, D. E. Hill, E. Healy, J. L. Rees, S. R. Hamilton, et al. 1995. Topological control of *p21WAF1/CIP1* expression in normal and neoplastic tissues. *Cancer Res.* **55**:2910–2919.
- Espinosa, J. M., R. E. Verdun, and B. M. Emerson. 2003. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. *Mol. Cell* **12**:1015–1027.
- Euskirchen, G., T. E. Royce, P. Bertone, R. Martone, J. L. Rinn, F. K. Nelson, F. Sayward, N. M. Luscombe, P. Miller, M. Gerstein, S. Weissman, and M. Snyder. 2004. CREB binds to multiple loci on human chromosome 22. *Mol. Cell. Biol.* **24**:3804–3814.
- Fang, L., G. Li, G. Liu, S. W. Lee, and S. A. Aaronson. 2001. p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. *EMBO J.* **20**:1931–1939.
- Fiscella, M., H. Zhang, S. Fan, K. Sakaguchi, S. Shen, W. E. Mercer, G. F. Vande Woude, P. M. O'Connor, and E. Appella. 1997. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. *Proc. Natl. Acad. Sci. USA* **94**:6048–6053.
- Fiucci, G., S. Beaucourt, D. Duflaut, A. Lespagnol, P. Stumpfner-Cuvelette, A. Geant, G. Buchwalter, M. Tuynder, L. Susini, J. M. Lassalle, C. Waslyk, B. Waslyk, M. Oren, R. Amson, and A. Telerman. 2004. Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. *Proc. Natl. Acad. Sci. USA* **101**:3510–3515.
- Flatt, P. M., J. O. Price, A. Shaw, and J. A. Pietenpol. 1998. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. *Cell Growth Differ.* **9**:535–543.
- Flatt, P. M., L. J. Tang, C. D. Scatena, S. T. Szak, and J. A. Pietenpol. 2000. p53 regulation of G₂ checkpoint is retinoblastoma protein dependent. *Mol. Cell Biol.* **20**:4210–4223.
- Gietz, R. D., and R. A. Woods. 2002. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. *Methods Enzymol.* **350**:87–96.

26. Gill, G. 2004. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? *Genes Dev.* **18**:2046–2059.

27. Grimshaw, M. J., S. Naylor, and F. R. Balkwill. 2002. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. *Mol. Cancer Ther.* **1**:1273–1281.

28. Grimshaw, M. J., J. L. Wilson, and F. R. Balkwill. 2002. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. *Eur. J. Immunol.* **32**:2393–2400.

29. Hanawalt, P. C. 2001. Controlling the efficiency of excision repair. *Mutat. Res.* **485**:3–13.

30. Harms, K., S. Nozell, and X. Chen. 2004. The common and distinct target genes of the p53 family transcription factors. *Cell Mol. Life Sci.* **61**:822–842.

31. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. *Nature* **387**:296–299.

32. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA* **95**:2509–2514.

33. Ho, J., and S. Benchimol. 2003. Transcriptional repression mediated by the p53 tumor suppressor. *Cell Death Differ.* **10**:404–408.

34. Hoh, J., S. Jin, T. Parrado, J. Edington, A. J. Levine, and J. Ott. 2002. The p53MH algorithm and its application in detecting p53-responsive genes. *Proc. Natl. Acad. Sci. USA* **99**:8467–8472.

35. Horak, C. E., M. C. Mahajan, N. M. Luscombe, M. Gerstein, S. M. Weissman, and M. Snyder. 2002. GATA-1 binding sites mapped in the beta-globin locus by using mammalian ChIP-chip analysis. *Proc. Natl. Acad. Sci. USA* **99**:2924–2929.

36. Impey, S., S. R. McCorkle, H. Cha-Molstad, J. M. Dwyer, G. S. Yochum, J. M. Boss, S. McWeeney, J. J. Dunn, G. Mandel, and R. H. Goodman. 2004. Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. *Cell* **119**:1041–1054.

37. Kapranov, P., S. E. Cawley, J. Drenkow, S. Bekiranov, R. L. Strausberg, S. P. Fodor, and T. R. Gingeras. 2002. Large-scale transcriptional activity in chromosomes 21 and 22. *Science* **296**:916–919.

38. Kashiwaba, M., K. Katsura, M. Ohnishi, M. Sasaki, H. Tanaka, Y. Nishimune, T. Kobayashi, and S. Tamura. 2003. A novel protein phosphatase 2C family member (PP2Czeta) is able to associate with ubiquitin-conjugating enzyme 9. *FEBS Lett.* **538**:197–202.

39. Kemp, T. J., T. J. Sadusky, F. Saltisi, N. Carey, J. Moss, S. Y. Yang, D. A. Sasso, G. Goldspink, and G. R. Coulton. 2000. Identification of Ankrd2, a novel skeletal muscle gene coding for a stretch-responsive ankyrin-repeat protein. *Genomics* **66**:229–241.

40. Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. *Science* **252**:1708–1710.

41. Kirmizis, A., and P. J. Farnham. 2004. Genomic approaches that aid in the identification of transcription factor target genes. *Exp. Biol. Med. (Maywood)* **229**:705–721.

42. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. *Nature* **387**:299–303.

43. Leng, R. P., Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G. Lozano, R. Hakem, and S. Benchimol. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. *Cell* **112**:779–791.

44. Li, X., A. Ponten, K. Aase, L. Karlsson, A. Abramsson, M. Uutela, G. Backstrom, M. Hellstrom, H. Bostrom, H. Li, P. Soriano, C. Betsholtz, C. H. Heldin, K. Alitalo, A. Ostman, and U. Eriksson. 2000. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. *Nat. Cell Biol.* **2**:302–309.

45. Ljungman, M., and F. Zhang. 1996. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. *Oncogene* **13**:823–831.

46. Ludes-Meyers, J. H., M. A. Subler, C. V. Shivakumar, R. M. Munoz, P. Jiang, J. E. Bigger, D. R. Brown, S. P. Deb, and S. Deb. 1996. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. *Mol. Cell. Biol.* **16**:6009–6019.

47. Mao, D. Y., J. D. Watson, P. S. Yan, D. Barsyte-Lovejoy, F. Khosravi, W. W. Wong, P. J. Farnham, T. H. Huang, and L. Z. Penn. 2003. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. *Curr. Biol.* **13**:882–886.

48. Martone, R., G. Euskirchen, P. Bertone, S. Hartman, T. E. Royce, N. M. Luscombe, J. L. Rinn, F. K. Nelson, P. Miller, M. Gerstein, S. Weissman, and M. Snyder. 2003. Distribution of NF- κ B-binding sites across human chromosome 22. *Proc. Natl. Acad. Sci. USA* **100**:12247–12252.

49. Metcalfe, A. M., R. M. Dixon, and G. K. Radda. 1997. Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter. *Nucleic Acids Res.* **25**:983–986.

50. Nakamura, Y. 2004. Isolation of p53-target genes and their functional analysis. *Cancer Sci.* **95**:7–11.

51. Nigro, J. M., R. Sikorski, S. I. Reed, and B. Vogelstein. 1992. Human p53 and *CDC2Hs* genes combine to inhibit the proliferation of *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **12**:1357–1365.

52. Ota, T., Y. Suzuki, T. Nishikawa, T. Otsuki, T. Sugiyama, R. Irie, A. Wakamatsu, K. Hayashi, H. Sato, K. Nagai, K. Kimura, H. Makita, M. Sekine, M. Obayashi, T. Nishi, T. Shibahara, T. Tanaka, S. Ishii, J. Yamamoto, K. Saito, Y. Kawai, Y. Isono, Y. Nakamura, K. Nagahari, K. Murakami, T. Yasuda, T. Iwayanagi, M. Wagatsuma, A. Shiratori, H. Sudo, T. Hosoiri, Y. Kaku, H. Kodaira, H. Kondo, M. Sugawara, M. Takahashi, K. Kanda, T. Yokoi, T. Furuya, E. Kikkawa, Y. Omura, K. Abe, K. Kamihara, N. Katsuta, K. Sato, M. Tanikawa, M. Yamazaki, K. Ninomiya, T. Ishibashi, H. Yamashita, K. Murakawa, K. Fujimori, H. Tanai, M. Kimata, M. Watanabe, S. Hiraoka, Y. Chiba, S. Ishida, Y. Ono, S. Takiguchi, S. Watanabe, M. Yosida, T. Hotuta, J. Kusano, K. Kanehori, A. Takahashi-Fujii, H. Hara, T. O. Tanase, Y. Nomura, S. Togya, F. Komai, R. Hara, K. Takeuchi, M. Arita, N. Imose, K. Musashino, H. Yuuki, A. Oshima, N. Sasaki, S. Aotsuka, Y. Yoshikawa, H. Matsunawa, T. Ichihara, N. Shiohata, S. Sano, S. Moriya, H. Momiyama, N. Satoh, S. Takami, Y. Terashima, O. Suzuki, S. Nakagawa, A. Senoh, H. Mizoguchi, Y. Goto, F. Shimizu, H. Wakebe, H. Hishigaki, T. Watanabe, A. Sugiyama, et al. 2004. Complete sequencing and characterization of 21,243 full-length human cDNAs. *Nat. Genet.* **36**:40–45.

53. Park, W. R., and Y. Nakamura. 2005. p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway. *Cancer Res.* **65**:1197–1206.

54. Qian, H., T. Wang, L. Naumovski, C. D. Lopez, and R. K. Brachmann. 2002. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. *Oncogene* **21**:7901–7911.

55. Ren, B., H. Cam, Y. Takahashi, T. Volkert, J. Terragni, R. A. Young, and B. D. Dynlacht. 2002. E2F integrates cell cycle progression with DNA repair, replication, and G₂/M checkpoints. *Genes Dev.* **16**:245–256.

56. Revenkova, E., J. Masson, C. Koncz, K. Afsar, L. Jakovleva, and J. Paszkowski. 1999. Involvement of *Arabidopsis thaliana* ribosomal protein S27 in mRNA degradation triggered by genotoxic stress. *EMBO J.* **18**:490–499.

57. Rinn, J. L., G. Euskirchen, P. Bertone, R. Martone, N. M. Luscombe, S. Hartman, P. M. Harrison, F. K. Nelson, P. Miller, M. Gerstein, S. Weissman, and M. Snyder. 2003. The transcriptional activity of human chromosome 22. *Genes Dev.* **17**:529–540.

58. Rubbi, C. P., and J. Milner. 2003. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. *EMBO J.* **22**:6068–6077.

59. Rubbi, C. P., and J. Milner. 2003. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. *EMBO J.* **22**:975–986.

60. Saha, S., A. B. Sparks, C. Rago, V. Akmaev, C. J. Wang, B. Vogelstein, K. W. Kinzler, and V. E. Velculescu. 2002. Using the transcriptome to annotate the genome. *Nat. Biotechnol.* **20**:508–512.

61. Shin, T. H., A. J. Paterson, and J. E. Kudlow. 1995. p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. *Mol. Cell. Biol.* **15**:4694–4701.

62. Stambolic, V., D. MacPherson, D. Sas, Y. Lin, B. Snow, Y. Jang, S. Benchimol, and T. W. Mak. 2001. Regulation of PTEN transcription by p53. *Mol. Cell.* **8**:317–325.

63. Stampfer, M., P. Yaswen, and J. Taylor-Papadimitriou. 2002. Culture of human mammary epithelial cells, p. 109–114. In R. I. Freshney and M. G. Freshney (ed.), *Culture of epithelial cells*, 2nd ed. Wiley-Liss, Inc., New York, N.Y.

64. Stewart, Z. A., and J. A. Pietenpol. 2001. p53 signaling and cell cycle checkpoints. *Chem. Res. Toxicol.* **14**:243–263.

65. Strausberg, R. L., E. A. Feingold, L. H. Grouse, J. G. Derge, R. D. Klausner, F. S. Collins, L. Wagner, C. M. Shenmen, G. D. Schuler, S. F. Altschul, B. Zeeberg, K. H. Buetow, C. F. Schaefer, N. K. Bhat, R. F. Hopkins, H. Jordan, T. Moore, S. I. Max, J. Wang, F. Hsieh, L. Diatchenko, K. Marusina, A. A. Farmer, G. M. Rubin, L. Hong, M. Stapleton, M. B. Soares, M. F. Bonaldo, T. L. Casavant, T. E. Scheetz, M. J. Brownstein, T. B. Usdin, S. Toshiyuki, P. Carninci, C. Prange, S. S. Raha, N. A. Loquellano, G. J. Peters, R. D. Abramson, S. J. Mullahy, S. A. Bosak, P. J. McEwan, K. J. McKernan, J. A. Malek, P. H. Gunaratne, S. Richards, K. C. Worley, S. Hale, A. M. Garcia, L. J. Gay, S. W. Hulyk, D. K. Villalon, D. M. Muzny, E. J. Sodergren, X. Lu, R. A. Gibbs, J. Fahey, E. Helton, M. Kettman, A. Madan, S. Rodrigues, A. Sanchez, M. Whiting, A. C. Young, Y. Shevchenko, G. G. Bouffard, R. W. Blakesley, J. W. Touchman, E. D. Green, M. C. Dickson, A. C. Rodriguez, J. Grimwood, J. Schmutz, R. M. Myers, Y. S. Butterfield, M. I. Krzywinski, U. Skalska, D. E. Smailus, A. Schnerch, J. E. Schein, S. J. Jones, and M. A. Marra. 2002. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. *Proc. Natl. Acad. Sci. USA* **99**:16899–16903.

66. Szak, S. T., D. Mays, and J. A. Pietenpol. 2001. Kinetics of p53 binding to promoter sites in vivo. *Mol. Cell. Biol.* **21**:3375–3386.

67. Takekawa, M., M. Adachi, A. Nakahata, I. Nakayama, F. Itoh, H. Tsukuda, Y. Taya, and K. Imai. 2000. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. *EMBO J.* **19**:6517–6526.

68. Tan, T., and G. Chu. 2002. p53 binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. *Mol. Cell. Biol.* **22**:3247–3254.

69. Tokino, T., S. Thiagalingam, W. S. El-Deiry, T. Waldmann, K. W. Kinzler, and B. Vogelstein. 1994. p53 tagged sites from human genomic DNA. *Hum. Mol. Genet.* **3**:1537–1542.

70. Ueda, K., H. Arakawa, and Y. Nakamura. 2003. Dual-specificity phosphatase

5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. *Oncogene* **22**:5586–5591.

71. Venter, J. C., M. D. Adams, E. W. Myers, P. W. Li, R. J. Mural, G. G. Sutton, H. O. Smith, M. Yandell, C. A. Evans, R. A. Holt, J. D. Gocayne, P. Amanatides, R. M. Ballew, D. H. Huson, J. R. Wortman, Q. Zhang, C. D. Kodira, X. H. Zheng, L. Chen, M. Skupski, G. Subramanian, P. D. Thomas, J. Zhang, G. L. Gabor Miklos, C. Nelson, S. Broder, A. G. Clark, J. Nadeau, V. A. McKusick, N. Zinder, A. J. Levine, R. J. Roberts, M. Simon, C. Slayman, M. Hunkapiller, R. Bolanos, A. Delcher, I. Dew, D. Fasulo, M. Flanigan, L. Florea, A. Halpern, S. Hannenhalli, S. Kravitz, S. Levy, C. Mobarry, K. Reinert, K. Remington, J. Abu-Threideh, E. Beasley, K. Biddick, V. Bonazzi, R. Brandon, M. Cargill, I. ChandramouliSwaran, R. Charlab, K. Chaturvedi, Z. Deng, V. Di Francesco, P. Dunn, K. Eilbeck, C. Evangelista, A. E. Gabrielian, W. Gan, W. Ge, F. Gong, Z. Gu, P. Guan, T. J. Heiman, M. E. Higgins, R. R. Ji, Z. Ke, K. A. Ketchum, Z. Lai, Y. Lei, Z. Li, J. Li, Y. Liang, X. Lin, F. Lu, G. V. Merkulov, N. Milshina, H. M. Moore, A. K. Naik, V. A. Narayan, B. Neelam, D. Nusskern, D. B. Rusch, S. Salzberg, W. Shao, B. Shue, J. Sun, Z. Wang, A. Wang, X. Wang, J. Wang, M. Wei, R. Wides, C. Xiao, C. Yan, et al. 2001. The sequence of the human genome. *Science* **291**:1304–1351.

72. Westfall, M. D., D. J. Mays, J. C. Snieszek, and J. A. Pietenpol. 2003. The ΔNp63 α phosphoprotein binds the p21 and 14-3-3 σ promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. *Mol. Cell. Biol.* **23**:2264–2276.

73. Wilson, T. E., T. J. Fahrner, M. Johnston, and J. Milbrandt. 1991. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. *Science* **252**:1296–1300.

74. Yamaizumi, M., and T. Sugano. 1994. u.v.-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes independent of the cell cycle. *Oncogene* **9**:2775–2784.

75. Yin, Y., Y. X. Liu, Y. J. Jin, E. J. Hall, and J. C. Barrett. 2003. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. *Nature* **422**:527–531.

76. Yu, J., L. Zhang, P. M. Hwang, C. Rago, K. W. Kinzler, and B. Vogelstein. 1999. Identification and classification of p53-regulated genes. *Proc. Natl. Acad. Sci. USA* **96**:14517–14522.

77. Zauberman, A., D. Flusberg, Y. Haupt, Y. Barak, and M. Oren. 1995. A functional p53-responsive intronic promoter is contained within the human *mdm2* gene. *Nucleic Acids Res.* **23**:2584–2592.

78. Zhang, Q. H., M. Ye, X. Y. Wu, S. X. Ren, M. Zhao, C. J. Zhao, G. Fu, Y. Shen, H. Y. Fan, G. Lu, M. Zhong, X. R. Xu, Z. G. Han, J. W. Zhang, J. Tao, Q. H. Huang, J. Zhou, G. X. Hu, J. Gu, S. J. Chen, and Z. Chen. 2000. Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34 $^{+}$ hematopoietic stem/progenitor cells. *Genome Res.* **10**:1546–1560.

79. Zhao, R. B., K. Gish, M. Murphy, Y. X. Yin, D. Notterman, W. H. Hoffman, E. Tom, D. H. Mack, and A. J. Levine. 2000. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. *Genes Dev.* **14**:981–993.

80. Zhu, J., and X. Chen. 2000. MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G₂-M. *Mol. Cell. Biol.* **20**:5602–5618.